Australian public assessment for Paliperidone palmitate

The combined exposure to Invega Trinza in the 3 studies included in this submission was 567.6 patient-years, based on 1,191 subjects (308 from PSY-1005, 379 from PSY-3012 and 504 from PSY-3011) who received at least 1 dose of Invega Trinza with 319 subjects (291 from PSY-3011 and 28 from PSY-3012) having at least 48 weeks of Invega Trinza. ................
................